You're not bringing anything new to the table by posting a verbose version of what I've already said, several times now -- that 3 of the 5 Bavi AC phase II's did not have any safety issues listed in the primary or secondary outcomes.
The fact that management did not list any safety issues in the primary or secondary outcome measures for these trials can only mean one thing; the risk of unexpected adverse reactions is low enough that safety is not an issue.
Market Data 
Markets 
AI
